A Study to Evaluate AMG 133 in Chinese Participants With Obesity or Overweight - Trial NCT06352892
Access comprehensive clinical trial information for NCT06352892 through Pure Global AI's free database. This Phase 1 trial is sponsored by Amgen and is currently Not yet recruiting. The study focuses on Obesity. Target enrollment is 20 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Amgen
Timeline & Enrollment
Phase 1
Apr 24, 2024
Sep 03, 2024
Primary Outcome
Maximum Observed Plasma Concentration (Cmax) of AMG 133,Area Under the Plasma Concentration-time Curve (AUC) from Time Zero to the Last Quantifiable Concentration (AUClast) of AMG 133,AUC from Time Zero Extrapolated to Infinity (AUCinf) of AMG 133
Summary
The main objective of the study is to assess the pharmacokinetics (PK) of AMG 133 after a
 single subcutaneous (SC) administration in overweight or obese Chinese participants.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06352892
Non-Device Trial